Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel. * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of A

Trial Details

NCT ID
NCT06710132
Phase
PHASE1 / PHASE2
Sponsor
EMD Serono Research & Development Institute, Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • M9140
Locations (sample)
  • Santa Monica, California, United States|34.01949,-118.49138
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Margate, Florida, United States|26.24453,-80.20644
  • Greenville, South Carolina, United States|34.85262,-82.39401
  • Memphis, Tennessee, United States|35.14953,-90.04898

Key Eligibility Criteria

  • Participants are capable of signing informed consent as defined in protocol
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) below or equal to 1
  • Participants with adequate hematologic, hepatic and renal function as defined in protocol
  • Participant must have at least 1 lesion that is measurable using RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →